neuroinfuse™ drug delivery system
Novel chronic and acute catheter systems for direct delivery of therapeutics to the brain
Crossing the blood-brain barrier
Intraparenchymal drug delivery offers a practical method of bypassing the blood-brain barrier and shows great promise in providing the next step change in the treatment of neurodegenerative, neuro oncology and other debilitating neurological conditions.
We are developing a patented range of engineering solutions to cover chronic (long term implantable) and acute (short term implantable) intraparenchymal drug delivery. Our low dead volume chronic device has a novel, MRI compatible, transcutaneous port that aims to provide a solution for simultaneous intermittent drug delivery through multiple catheters (up to four) at any time interval.
Watch an introductory video
Working with clinical partners
Over several years Renishaw has been working with experienced clinical experts to produce a specification for an intraparenchymal drug delivery device and stereotactic delivery platform that facilitates convection enhanced delivery (CED) and other infusion applications.
The chronic product is currently undergoing clinical investigation as part of the Horizon 2020 funded TreatER project. TreatER is a first-in-human clinical study examining the intraparenchymal delivery of CDNF for the treatment of Parkinson's disease.
Drug development opportunities
At present, the Renishaw neuroinfuse™ drug delivery system can only be used in the setting of an approved clinical trial. Renishaw is currently seeking academic, clinical and industrial partners across a wide range of indications, from oncology to neurodegenerative diseases. The purpose of this website is only to obtain partners and not to make the device generally available.